ArticleArtificial organs2026
In Vitro Hemolytic Performance of the Novel Realheart Total Artificial Heart Versus SynCardia Total Artificial Heart With Human Blood.
Article in Artificial organs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe SynCardia Total Artificial Heart (TAH) is FDA-approved for bridge to transplantation and has been implanted in over 2000 patients. While hemolysis has been reported postimplantation, no published in vitro test data assess hemolysis or hematology. The Realheart TAH is a novel four-chamber pulsatile positive displacement TAH which mimics the natural heart's atrioventricular plane movement for physiological flow patterns and gentle blood handling. This study evaluates in vitro hemolytic performance of the SynCardia TAH against a newer prototype of the Realheart TAH, V11.2, using human blood.
methodsHemolysis testing followed ASTM standards, F1830-97 and F1841-97 (2017) using pooled human whole blood diluted to a hematocrit of 30% ± 2%. The targeted flow and pressure head were 5 ± 0.25 L/min and 100 mmHg, respectively. Hematology parameters were analyzed, plasma free hemoglobin (pfHb) was measured, and milligram normalized index of hemolysis (mgNIH) and modified index of hemolysis (MIH) were calculated. Statistical analyses were performed.
resultsMean mgNIH (n = 6) were 18.11 ± 3.53 mg/100 L for V11.2 and 37.15 ± 12.42 mg/100 L for SynCardia (p < 0.05), a 2.05-fold increase in SynCardia TAH. MIH values were 1.69 ± 0.31 for V11.2 and 3.67 ± 1.29 for SynCardia (p < 0.05). Compared with the static control, SynCardia significantly reduced erythrocyte and increased platelet counts, effects not observed with the V11.2, whereas V11.2 significantly reduced leukocyte counts relative to the control.
conclusionRealheart TAH V11.2 exhibited significantly lower hemolysis than SynCardia TAH in a modified systemic circulation test rig, indicating better hemocompatibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.